HomeComparePIFMF vs PFE

PIFMF vs PFE: Dividend Comparison 2026

PIFMF yields 3.46% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PIFMF wins by $555.6K in total portfolio value
10 years
PIFMF
PIFMF
● Live price
3.46%
Share price
$0.50
Annual div
$0.02
5Y div CAGR
56.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$605.1K
Annual income
$364,129.76
Full PIFMF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PIFMF vs PFE

📍 PIFMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPIFMFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PIFMF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PIFMF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PIFMF
Annual income on $10K today (after 15% tax)
$294.10/yr
After 10yr DRIP, annual income (after tax)
$309,510.30/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PIFMF beats the other by $287,190.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PIFMF + PFE for your $10,000?

PIFMF: 50%PFE: 50%
100% PFE50/50100% PIFMF
Portfolio after 10yr
$327.3K
Annual income
$195,194.24/yr
Blended yield
59.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PIFMF
No analyst data
Altman Z
2.0
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PIFMF buys
0
PFE buys
0
No recent congressional trades found for PIFMF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPIFMFPFE
Forward yield3.46%6.13%
Annual dividend / share$0.02$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR56.1%13.2%
Portfolio after 10y$605.1K$49.6K
Annual income after 10y$364,129.76$26,258.71
Total dividends collected$559.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PIFMF vs PFE ($10,000, DRIP)

YearPIFMF PortfolioPIFMF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,240$540.11$9,153$693.39+$2.1KPIFMF
2$12,913$885.66$8,593$849.25+$4.3KPIFMF
3$15,301$1,484.33$8,336$1,066.78+$7.0KPIFMF
4$18,938$2,565.96$8,437$1,384.80+$10.5KPIFMF
5$24,897$4,633.24$9,013$1,875.40+$15.9KPIFMF
6$35,526$8,886.20$10,306$2,680.72+$25.2KPIFMF
7$56,511$18,498.48$12,820$4,101.38+$43.7KPIFMF
8$103,395$42,928.47$17,673$6,826.70+$85.7KPIFMF
9$225,219$114,586.18$27,543$12,591.86+$197.7KPIFMF
10$605,114$364,129.76$49,560$26,258.71+$555.6KPIFMF

PIFMF vs PFE: Complete Analysis 2026

PIFMFStock

PT Indofood Sukses Makmur Tbk operates as a food solutions company in Indonesia and internationally. It operates through four segments: Consumer Branded Products Business Group, Bogasari Business Group, Agribusiness Group, and Distribution Business Group. The company offers noodles; ultra-high temperature (UHT), sterilized bottled, evaporated, pasteurized liquid, UHT multi-cereal, and powdered milk; milk-flavored and cereal powdered drinks, sweetened condensed creamer, ice cream, and butter; potato, cassava, soybean, corn, and various extruded snacks; recipe mixes, soy and chili sauce, tomato sauce, and stock soup; baby cereals; rice puffs, crunchies, biscuits, puddings, noodle soup, and pasta; cereal snacks for children; and ready-to-drink tea, packaged water, and fruit-flavored drinks. It also produces wheat flour, pasta, and coffee; distributes consumer products; manufactures and markets cooking oils, margarine, and shortening; cultivates sugar cane, rubber, industrial timber, cocoa, coconut, tea plantations, and other crops; extracts and processes coconut oil; operates bulking station; processes oils and fat; and markets and distributes culinary products. In addition, the company engages in the research and development, seed breeding, and oil palm cultivation and milling activities; shipping, investment and management, trade export agency, industrial estate agriculture, forestry, fishing, and trading and marketing activities; ownership and management of buildings; chain restaurant management; flour milling, blending, and trading; and provision of transportation, management consulting, and research management and technical services, as well as packaging materials and fertilizers. The company was formerly known as PT Panganjaya Intikusuma and changed its name to PT Indofood Sukses Makmur Tbk in 1994. The company was incorporated in 1990 and is based in Jakarta, Indonesia. PT Indofood Sukses Makmur Tbk is a subsidiary of First Pacific Investment Management Limited.

Full PIFMF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PIFMF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PIFMF vs SCHDPIFMF vs JEPIPIFMF vs OPIFMF vs KOPIFMF vs MAINPIFMF vs JNJPIFMF vs MRKPIFMF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.